Everolimus for advanced renal cell carcinoma after previous treatment

Equality Impact Assessment (Guidance development) (PDF 221 KB)

Final appraisal determination

Final appraisal determination document (PDF 433 KB)

Committee papers (PDF 4.13 MB)

Final scope (PDF 104 KB)

Final matrix (PDF 93 KB)

Appeal

Novartis : Written submission (PDF 98 KB)

Novartis : Scrutiny letter (PDF 38 KB)

Novartis : Response to scrutiny letter (PDF 60 KB)

Novartis Appendix 1 : Response to scrutiny letter (PDF 27 KB)

Novartis Appendix 2 : Response to scrutiny letter (PDF 18 KB)

Novartis Appendix 3 : Response to scrutiny letter (PDF 40 KB)

Novartis Appendix 3a : Response to scrutiny letter (PDF 137 KB)

Novartis Appendix 3b : Response to scrutiny letter (PDF 65 KB)

Novartis : Final scrutiny letter (PDF 26 KB)

Kidney Cancer UK : Written submission (PDF 873 KB)

Kidney Cancer UK : Scrutiny letter (PDF 23 KB)

Kidney Cancer UK : Response to scrutiny letter (PDF 15 KB)

Kidney Cancer UK : Final scrutiny letter (PDF 14 KB)

James Whale Fund : Written submission (PDF 26 KB)

James Whale Fund : Scrutiny letter (PDF 26 KB)

James Whale Fund : Final scrutiny letter (PDF 14 KB)

Consultation document FAD2 (PDF 262 KB)

Committee papers Evaluation report (PDF 784 KB)

Consultation document FAD (PDF 157 KB)

Committee papers Evaluation Report (PDF 1.16 MB)

Consultation document (PDF 145 KB)

Committee papers Evaluation Report (PDF 2.78 MB)

Final scope (PDF 39 KB)

Final matrix (PDF 31 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 91 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 25 KB)